We conducted a single-blind, two-period randomized cross-over clinical trial study to investigate the benefits of allopurinol treatment in hyperuricemic patients for reduction of high blood pressure (BP) in HD patients. A total of 53 patients enrolled in this study. Patients were randomly assigned into allopurinol (n:28) or control (n:27) groups. Patients in allopurinol group received 100 mg/day allopurinol for three months at the first phase of study. After that, patients passed two months washing period. Then, allopurinol was administrated for another three-month period followed by cross-over in second phase. The systolic and diastolic blood pressures were measured before and after dialysis at the first dialysis session of each week. Uric acid was also measured every month.
General information
Acronym
IRCT registration information
IRCT registration number:IRCT138902043325N2
Registration date:2010-04-24, 1389/02/04
Registration timing:retrospective
Last update:
Update count:0
Registration date
2010-04-24, 1389/02/04
Registrant information
Name
Majgan Jalalzadeh
Name of organization / entity
Zanjan University Of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 24 1426 6934
Email address
jmojgan@zums.ac.ir
Recruitment status
Recruitment complete
Funding source
Zanjan University of Medical Sciences
Expected recruitment start date
2009-04-24, 1388/02/04
Expected recruitment end date
2009-06-26, 1388/04/05
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of treatment of hyperuricemia on lowering blood pressure in hemodialysis patients: single-blind, two-period randomized cross-over study
Public title
Effect of Allopurinol in lowering blood pressure in hemodialysis patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: having high level of serum uric acid (serum uric acid level greater than 6.5 mg/dl (men) or greater than 5.5 mg/dl (women). This definition was based on analyses from the Atherosclerosis Risk in Communities (ARIC) Study;
Exclusion criteria: uric acid level of serum less than 6.5 for men and less than 5.5 for women, known history of allopurinol hypersensitivity or those who already were on allopurinol
Age
No age limit
Gender
Both
Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size:
55
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Single blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Zanjan University of Medical Sciences
Street address
faculty of medicine, Zanjan University of Medical Sciences, shahrake karmandan, zanjan, iran